

Therapeutic Class Report Overview : Hepatitis C Virus Infection

<https://marketpublishers.com/r/T0F0BF772A4EN.html>

Date: February 2013

Pages: 31

Price: US\$ 1,000.00 (Single User License)

ID: T0F0BF772A4EN

Abstracts

The launch of Protease inhibitors' (PIs) created a wave in 2011-12 and accelerated the pace of innovation and impressive Sustained Virologic Response (SVR) rates by oral IFN free drug combinations have raised the bar and the expectations of pts, physicians and investors. Freedom from IFN, treating all genotypes and betting on vaccines could bring a sea of change in the HCV therapy class area in the future.

Roche set the trend with the acquisition of Anadys for total of \$230m followed by GILD buying VRUS for \$11b, Bristol-Myers Squibb (BMY) acquired Inhibitex for \$2.5b, VRTX acquired Virochem in 2009 for \$375m + in-licensed Alios' VX-135 in 2012 for total of \$775m, and Abbott in-licensed Enanta's ABT-450 for total of ~\$310m. In the next spurt of M&A in this sector, we expect companies which offer differentiated MOA to be in the limelight, are (i) Alleviate the need for Ribavarin, (ii) Address resistance, non-responders, Liver cirrhosis, HIV-HCV –co infection etc, (iii) Target other genotypes, and (iv) Vaccines or Boosters of immune system (toll like receptors). In this report, we have analyzed the novel pipeline candidates, which target unmet needs, offer promise of an 'all oral IFN-free treatment' with at par or better efficacy / compliance, and novel vaccine candidates.

Contents

1. EXECUTIVE SUMMARY

2. PROGRESS IN THE CLINICAL DEVELOPMENT OF HCV DRUGS

Noteworthy progress in the Oral IFN –Free combinations for Treatment of HCV
Options for the most Challenging Patient Subtypes in HCV
IFN intolerant and other Genotypes
Hepatitis C Virus Prevalence in ROW

3. COMPETITIVE LANDSCAPE - IFN-FREE DRUGS

Gilead: Sofosbuvir/GS-5885
Abbott: ABT-450r/ABT-472/ABT-333
Boehringer Ingelheim: Faldaprevir/BI 207127
Medevir: Simeprevir
Vertex's VX-135
Bristol-Myers: Daclatasvir/Asunaprevir
Merck: MK-5172/MK-8742

4. MARKET DYNAMICS- PRESENT AND FUTURE

Present- Launch of Protease Inhibitors: Sunset Sooner Than Expected.
Future- the “Best-in-Class IFN-Free Oral Pill” for HCV

5. HCV VACCINES

GlobelImmune
Okairos
ChronTech Pharma/ Inovio
Transgene's TG4040
Profectus Biosciences' HCV vaccine
Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden

6. HCV-HIV CO-INFECTION

Effects of co-infection
Companies targeti ng HIV-HCV Co-infection

7. ANNEXURE

Figures – Designs of ongoing IFN-free PHIII trials

Table - Data from IFN-free combinations

Table - Viral response in genotype-1 patients – IFN-combinations

Key Abstract presented at AASLD '12

I would like to order

Product name: Therapeutic Class Report Overview : Hepatitis C Virus Infection

Product link: <https://marketpublishers.com/r/T0F0BF772A4EN.html>

Price: US\$ 1,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T0F0BF772A4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970